Semax Quick Start
Semax is a synthetic heptapeptide derived from a fragment of ACTH (adrenocorticotropic hormone), developed in Russia as a nootropic and neuroprotective agent. It is studied for cognition, focus, stress resilience, and recovery in neurological models, and is approved in Russia for several neurological indications. Intranasal delivery is the classic route.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
Semax Dosing Protocols
The nasal-spray, injectable (subcutaneous) and pen-vial formats are documented as separate protocols. Intranasal is the traditional Semax route, so the spray maps naturally to most published and community research. Ranges are research-planning references, not personal dosing recommendations.
Nasal Spray (classic route)
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Low | 200 mcg | 2 sprays | 1–2× daily |
| Standard | 400 mcg | 4 sprays | 1–2× daily |
| High | 600 mcg | 6 sprays | 1–2× daily |
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Low | 200 mcg | 1–2× daily |
| Standard | 400 mcg | 1–2× daily |
| High | 600 mcg | 1–2× daily |
Pen Vial — Pre-Reconstituted 3 mL
| Band | Per dose (units) | Delivers | Frequency |
|---|---|---|---|
| Low | 6 units | 200 mcg | 1–2× daily |
| Standard | 12 units | 400 mcg | 1–2× daily |
| High | 18 units | 600 mcg | 1–2× daily |
Semax is short-acting; split daily dosing appears frequently in research planning. It is often researched in blocks of a few weeks. (N-Acetyl Semax is a separate, longer-acting variant.)
Semax Reconstitution Guide
Semax ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays and pen vials both ship ready to use — the pen at a fixed 3 mL fill, so no water is added to it at all.
Injection
| BAC | Conc. | 200 mcg |
|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.04 mL · 4 u |
| 3 mL | 3,333 mcg/mL | 0.06 mL · 6 u |
Vial holds up to ~3 mL; 2 mL is the default. Units are U-100.
Pen Vial — 3 mL
| Format | Conc. | 200 mcg |
|---|---|---|
| 3 mL (as supplied) | 3,333 mcg/mL | 0.06 mL · 6 u |
Ships pre-reconstituted; no BAC water is added. 33.3 mcg per unit on a U-100 scale.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder.
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 2–3 mL into the vial for injection (vial max ~3 mL).
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until clear.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the pen vial
- Inspect the vial. Confirm the label and strength. The solution should be clear and colorless.
- Never add water. A pen vial ships at its final 3 mL volume. Adding bacteriostatic water would dilute it and invalidate every unit figure on this page.
- Load the vial into the pen. Unscrew the pen's cartridge holder, seat the vial, and screw the holder back on until firm.
- Attach a fresh needle tip. Screw a new disposable pen needle onto the holder, then pull off the outer and inner caps. Use a new tip for every dose.
- Prime the pen. Dial 2 units, hold the pen needle-up, tap the holder so any air rises to the top, and press the button until a drop appears at the tip. Repeat until it does.
- Spin to the dose. Turn the dial to the unit figure from the table above. If you overshoot, spin back — never press the button to correct an overshoot.
- Inject and hold. Press the button all the way down, then keep the needle in place for about ten seconds before withdrawing so the full dose is delivered.
- Remove and dispose of the needle. Unscrew the tip into a sharps container. Never store the pen with a needle attached — it lets solution leak out and air in.
- Cap and refrigerate. Store the pen with the vial still seated at 2–8 °C. Do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
How Semax Works
Semax is an analog of the ACTH(4–10) fragment but, unlike ACTH, it does not stimulate cortisol release. Research reports that it increases expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), modulates dopaminergic and serotonergic activity, and has neuroprotective and anti-inflammatory effects in the central nervous system. Its activity is enhanced by being relatively resistant to breakdown compared with the parent fragment.
BDNF / NGF
Reported to upregulate neurotrophic factors linked to neuronal survival and plasticity.
Neurotransmitters
Modulates dopaminergic and serotonergic signaling in research models.
Neuroprotection
Animal stroke/ischemia models report protective and recovery effects.
No cortisol effect
Despite the ACTH origin, Semax does not drive corticosteroid release.
Who Should Avoid Semax
Pregnancy & lactation
No human reproductive safety data outside its approved use context.
On psychoactive medications
Interactions with dopaminergic/serotonergic drugs aren't characterized; review with a clinician.
Nasal pathology
Active nasal injury or infection may make the intranasal route unsuitable.
Anyone seeking a treatment
Treat Semax as research context only, not a medical treatment.
Semax Side Effects & Safety
Generally well tolerated
In its approved-use context and research, Semax has a mild reported side-effect profile.
Nasal irritation
Mild irritation can occur with the intranasal route; alternate nostrils.
Overstimulation
Some users report feeling stimulated or alert; dose/timing adjustments are the usual response.
Quality-control risk
Verify identity and purity against a Certificate of Analysis.
Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| Same day | Focus / alertness self-report | Semax is short-acting; effects are evaluated acutely. |
| Week 1–3 | Cognitive/mood self-report over a block | Most community research runs in multi-week blocks. |
| Ongoing | Nasal tolerance (intranasal route) | Alternate nostrils; pause if irritation persists. |
Research Evidence Context
Russian clinical use
Approved in Russia for stroke, cognitive, and optic-nerve indications, supported by regional clinical data.
Neurotrophic research
Studies report BDNF/NGF upregulation and neuroprotection in animal and cell models.
Western evidence
Large Western RCTs are limited; outside Russia it is treated as research-use.
Open question
Translation of cognitive benefits to healthy-user contexts is not well established.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | More stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
Mistakes & Troubleshooting
- Nasal irritation. Alternate nostrils; pause if it persists. Consider the injectable format.
- Feeling over-stimulated. Lower the dose or avoid late-day administration.
- Missed dose. Skip and continue at the next scheduled time; Semax is short-acting.
- Left out overnight. Treat reconstituted solution as compromised and discard.
Semax vs Selank vs N-Acetyl Semax
| Feature | Semax | N-Acetyl Semax |
|---|---|---|
| Profile | ACTH(4–10) nootropic, short-acting | Acetylated, longer-acting variant |
| Route | Intranasal / SubQ | Intranasal / SubQ |
| Focus | Cognition, focus, neuroprotection; often compared with the anxiolytic peptide Selank. | |
Frequently Asked Questions
What is Semax?
A synthetic heptapeptide based on an ACTH fragment, developed in Russia as a nootropic and neuroprotective agent. It is approved in Russia for some neurological indications.
How is the nasal spray dosed vs the injection?
Separate protocols. Intranasal is the classic route: the spray delivers 100 mcg per spray, so 2–6 sprays covers the 200–600 mcg research range. Injection covers the same range subcutaneously.
How is Semax reconstituted?
The spray ships pre-mixed and delivers 100 mcg per spray. For injection, 10 mg in 2 mL gives 5,000 mcg/mL, so 200 mcg = 0.04 mL = 4 units.
Does Semax raise cortisol like ACTH?
No. Although it is derived from an ACTH fragment, Semax does not stimulate corticosteroid release.
What is the pen-vial format?
A 10 mg pen vial supplied already reconstituted to 3 mL — 300 units at 33.3 mcg per unit. A 200 mcg reference dose is 6 units. It maps to the injection protocol; the nasal spray remains the traditional route for Semax.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
Semax Formats & Sourcing
The protocols above are written against the formats Semax is actually supplied in. Batch-specific Certificates of Analysis are issued per lot; always verify the strength on the label against the figures used here before calculating anything.
| Format | Supplied as |
|---|---|
| Vial | 10 mg lyophilized powder |
| Pen vial | Pre-reconstituted, 3 mL |
| Nasal spray | Pre-mixed, 100 mcg per spray |
| Nasal spray — 5-pack | Bulk: five nasal spray units |
| Vial — 5-pack | Bulk: five vial units |
5-packs are available for the nasal spray and vial formats. Strengths and formats are listed as sold; confirm against the product page and the batch COA.
Reference material for this protocol, with batch COA:
View Semax on Spyro Peptides →References
- Ashmarin IP, et al. Semax: an ACTH(4–10) analog with nootropic properties. Neurosci Behav Physiol (review).
- Dolotov OV, et al. Semax and BDNF expression in the rat hippocampus. J Neurochem / Neurosci Lett (2006).
- Medvedeva EV, et al. Semax in cerebral ischemia models. Mol Biol / J Mol Neurosci (2014).
- Kaplan A, et al. Clinical use of Semax in ischemic stroke. Zh Nevrol Psikhiatr (review).